Drugs / Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01583686 | May 2012 → Dec 2018 | cervical cancer, lung cancer, malignant pancreatic neoplasm, mesothelioma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01583686 ↗ |
| Modality | Cell therapy | “anti-mesothelin CAR engineered peripheral blood lymphocytes” NCT01583686 ↗ |
| Route | Intravenous | “Cells will be infused intravenously (IV)” NCT01583686 ↗ |